6,118 Shares in Sanofi (NASDAQ:SNY) Acquired by Guggenheim Capital LLC

Guggenheim Capital LLC bought a new position in shares of Sanofi (NASDAQ:SNY) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,118 shares of the company’s stock, valued at approximately $295,000.

A number of other large investors have also recently added to or reduced their stakes in SNY. State Street Corp boosted its holdings in Sanofi by 0.5% during the third quarter. State Street Corp now owns 56,734 shares of the company’s stock worth $3,270,000 after buying an additional 264 shares in the last quarter. Barclays PLC boosted its stake in Sanofi by 107.5% in the 3rd quarter. Barclays PLC now owns 639,772 shares of the company’s stock worth $36,869,000 after purchasing an additional 331,445 shares during the period. Geode Capital Management LLC boosted its stake in Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after purchasing an additional 16,780 shares during the period. World Investment Advisors LLC boosted its stake in Sanofi by 1,020.5% in the 3rd quarter. World Investment Advisors LLC now owns 48,430 shares of the company’s stock worth $2,791,000 after purchasing an additional 44,108 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Sanofi in the 3rd quarter worth approximately $219,000. 14.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $63.33.

Sanofi Stock Down 2.3 %

SNY stock opened at $52.32 on Monday. The company has a market cap of $132.17 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 1.01 and a beta of 0.57. The company has a 50 day moving average of $54.53 and a two-hundred day moving average of $52.05. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio (DPR) is currently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.